Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development.

Fiebig T, Berti F, Freiberger F, Pinto V, Claus H, Romano MR, Proietti D, Brogioni B, Stummeyer K, Berger M, Vogel U, Costantino P, Gerardy-Schahn R.

Glycobiology. 2014 Feb;24(2):150-8. doi: 10.1093/glycob/cwt102. Epub 2013 Nov 20.

PMID:
24259400
2.

Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase.

Muindi KM, McCarthy PC, Wang T, Vionnet J, Battistel M, Jankowska E, Vann WF.

Glycobiology. 2014 Feb;24(2):139-49. doi: 10.1093/glycob/cwt091. Epub 2013 Oct 16.

PMID:
24134880
3.

Development and evaluation of a dipstick diagnostic test for Neisseria meningitidis serogroup X.

Agnememel A, Traincard F, Dartevelle S, Mulard L, Mahamane AE, Oukem-Boyer OO, Denizon M, Kacou-N Douba A, Dosso M, Gake B, Lombart JP, Taha MK.

J Clin Microbiol. 2015 Feb;53(2):449-54. doi: 10.1128/JCM.02444-14. Epub 2014 Nov 19.

4.

Molecular cloning and functional characterization of components of the capsule biosynthesis complex of Neisseria meningitidis serogroup A: toward in vitro vaccine production.

Fiebig T, Freiberger F, Pinto V, Romano MR, Black A, Litschko C, Bethe A, Yashunsky D, Adamo R, Nikolaev A, Berti F, Gerardy-Schahn R.

J Biol Chem. 2014 Jul 11;289(28):19395-407. doi: 10.1074/jbc.M114.575142. Epub 2014 May 21.

5.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

6.

Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.

Rossi R, Konar M, Beernink PT.

Infect Immun. 2016 May 24;84(6):1735-42. doi: 10.1128/IAI.01491-15. Print 2016 Jun.

7.

The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages.

Litschko C, Romano MR, Pinto V, Claus H, Vogel U, Berti F, Gerardy-Schahn R, Fiebig T.

J Biol Chem. 2015 Oct 2;290(40):24355-66. doi: 10.1074/jbc.M115.678094. Epub 2015 Aug 18.

8.

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Micoli F, Romano MR, Tontini M, Cappelletti E, Gavini M, Proietti D, Rondini S, Swennen E, Santini L, Filippini S, Balocchi C, Adamo R, Pluschke G, Norheim G, Pollard A, Saul A, Rappuoli R, MacLennan CA, Berti F, Costantino P.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19077-82. doi: 10.1073/pnas.1314476110. Epub 2013 Nov 4.

9.

The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.

Pinto VB, Burden R, Wagner A, Moran EE, Lee CH.

PLoS One. 2013 Nov 14;8(11):e79304. doi: 10.1371/journal.pone.0079304. eCollection 2013.

10.

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK.

Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.

PMID:
23261039
11.

Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Menéndez T, Carmenate T, Cruz-Leal Y, Coizeau E, Caballero E, Bello D, Guirola M, Alvarez A, Guillén G.

Curr Microbiol. 2010 Feb;60(2):79-84. doi: 10.1007/s00284-009-9505-9. Epub 2009 Sep 23.

PMID:
19771476
12.

Neisseria meningitidis serogroup B vaccine development.

Caesar NM, Myers KA, Fan X.

Microb Pathog. 2013 Apr;57:33-40. doi: 10.1016/j.micpath.2013.02.003. Epub 2013 Feb 14. Review. Erratum in: Microb Pathog. 2013 Jun-Jul;59-60:60.

PMID:
23416222
13.

Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005.

Alonso JM, Gilmet G, Rouzic EM, Nassif X, Plotkin SA, Ramsay M, Siegrist CA, Stephens DS, Teyssou R, Vogel U.

Vaccine. 2007 May 22;25(21):4125-9. Epub 2007 Mar 19.

PMID:
17449149
14.

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.

Xie O, Pollard AJ, Mueller JE, Norheim G.

Vaccine. 2013 Jun 12;31(27):2852-61. doi: 10.1016/j.vaccine.2013.04.036. Epub 2013 Apr 24. Review.

PMID:
23623866
15.

The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.

Jennings HJ.

Contrib Microbiol Immunol. 1989;10:151-65. Review. No abstract available.

PMID:
2479499
16.

Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.

Fischer M, Carlone GM, Holst J, Williams D, Stephens DS, Perkins BA.

Vaccine. 1999 May 14;17(19):2377-83.

PMID:
10392619
17.

Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135.

Tsang RS, Tsai CM, Henderson AM, Tyler S, Law DK, Zollinger W, Jamieson F.

Can J Microbiol. 2008 Mar;54(3):229-34. doi: 10.1139/w07-132.

PMID:
18388994
18.

Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.

Park IH, Lin J, Choi JE, Shin JS.

Mol Immunol. 2014 Jun;59(2):142-53. doi: 10.1016/j.molimm.2014.01.016. Epub 2014 Mar 4.

PMID:
24603121
19.

Development of new vaccines against meningococcal disease.

Bröker M.

Arzneimittelforschung. 2003;53(12):805-13. Review.

PMID:
14732960
20.

Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Diaz Romero J, Outschoorn IM.

Clin Microbiol Rev. 1994 Oct;7(4):559-75. Review.

Supplemental Content

Support Center